Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants

Next Previous
Trial Profile

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV DNA vaccine (Primary) ; HIV DNA vaccine (Primary) ; INO 9012; INO 9012
  • Indications HIV infections
  • Focus Adverse reactions

    • Most Recent Events

    • 12 Mar 2019 According to Inovio Pharmaceuticals media release, Inovio expects to have clinical data from several Phase 1 vaccine programs published multiple publications in 2019: Ebola vaccine; MERS vaccine; HIV; and ZIka vaccine study in Puerto Rico.
    • 14 Aug 2018 According to an Inovio Pharmaceuticals media release, results of this study are being prepared for a manuscript to be submitted for a publication in a medical journal.
    • 15 May 2018 According to an Inovio Pharmaceuticals media release, breakthrough data from this study was presented at a plenary session at the 2018 HVTN Full Group Meeting on May 14 in Washington, D.C.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top